发明名称 |
ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY |
摘要 |
The invention relates to pharmaceutical compositions for and methods of treatment with HER3-targeted combination therapy. The invention relates to pharmaceutical compositions comprising an oligomer which targets HER3 (and optionally one or more of HER2 and EGFR) mRNA in a cell, leading to reduced expression of HER3 and optionally HER2 and/or EGFR, and a small molecule protein tyrosine kinase inhibitor of one or more receptor tyrosine kinases, leading to inhibition of signaling and/or internalization of receptor dimers into the cell. The combination therapy is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides methods of treating hyperproliferative disorders with a combination of an oligomer and a protein tyrosine kinase inhibitor.
|
申请公布号 |
CA2741050(A1) |
申请公布日期 |
2010.05.14 |
申请号 |
CA20092741050 |
申请日期 |
2009.11.05 |
申请人 |
SANTARIS PHARMA A/S;ENZON PHARMACEUTICALS, INC. |
发明人 |
LIAO, BAISONG;ZHANG, YIXIAN |
分类号 |
A61K31/70;C07H21/04;C12N5/02 |
主分类号 |
A61K31/70 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|